Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and PARP-1 activity in Aβ(1-42)-induced rat model of Alzheimer's disease

Free Radical Research

Volumn 48, Issue 2, 2014, Pages 146-158

  Turunc Bayrakdar, E ^a   Uyanikgil, Y ^a   Kanit, L ^a   Koylu, E ^a   Yalcin, A ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Amyloid peptide; Apoptosis; Nicotinamide; Oxidative stress; PARP 1 inhibition

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ANTIOXIDANT; CATALASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BRAIN CORTEX; BRAIN SYNAPTOSOME; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE OVEREXPRESSION; HIPPOCAMPUS; LIPID PEROXIDATION; MALE; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN CARBONYLATION; RAT; TREATMENT DURATION; UPREGULATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIOXIDANTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CATALASE; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HIPPOCAMPUS; HUMANS; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; NEUROPROTECTIVE AGENTS; NF-KAPPA B; NIACINAMIDE; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; POLY(ADP-RIBOSE) POLYMERASES; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE; SYNAPTOSOMES;

EID: 84890048084     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2013.857018     Document Type: Article

References (91)

1. Selkoe DJ. Alzheimer disease: Mechanistic understanding predicts novel therapies. Ann Intern Med 2004; 140: 627-638.
2. Forlenza OV, Diniz BS, Gattaz WF. Diagnosis and biomarkers of predementia in Alzheimers disease. BMC Med 2010; 8: 89.
3. Blass JP. Alzheimer 'disease and Alzheimer 'dementia: Distinct but overlapping entities. Neurobiol Aging 2002; 23: 1077-1084.
4. Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 2004; 62: 1984-1989.
5. Butterfield DA, Drake J, Pocernich C, Castegna A. Evidence of oxidative damage in Alzheimers disease brain: Central role for amyloid beta-peptide. Trends Mol Med 2001; 7: 548-554.
6. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 2004; 430: 631-639.
7. Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 2000; 1: 120-129.
8. Block ML, Hong JS. Microglia and infl ammation-mediated neurodegeneration: Multiple triggers with a common mechanism. Prog Neurobiol 2005; 76: 77-98.
9. Steinbrenner H, Sies H. Protection against reactive oxygen species by selenoproteins. Biochim Biophys Acta 2009; 1790: 1478-1485.
10. Dringen R. Metabolism and functions of glutathione in brain. Prog Neurobiol 2000; 62: 649-671.
11. Packer L, Cadenas E. Oxidants and antioxidants revisited. New concepts of oxidative stress. Free Radic Res 2007; 41: 951-952.
12. Nicolakakis N, Hamel E. Neurovascular function in Alzheimer's disease patients and experimental models. J Cereb Blood Flow Metab 2011; 31: 1354-1370.
13. Sonnen JA, Breitner JC, Lovell MA, Markesbery WR, Quinn JF, Montine TJ. Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radic Biol Med 2 008; 4 5: 2 19-2 30.
14. Chambon C, Wegener N, Gravius A, Danysz W. Behavioural and cellular effects of exogenous amyloid- peptides in rodents. Behav Brain Res 2011; 225: 623-641.
15. Boyd-Kimball D, Sultana R, Poon HF, Lynn BC, Casamenti F, Pepeu G, et al. Proteomic identifi cation of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1-42) into rat brain: Implications for Alzheimer's disease. Neuroscience 2005; 132: 313-324.
16. G o tz J, Chen F, Van Dorpe J, Nitsch RM. Abeta42 fi brils induce the formation of neurofi brillary tangles in P301L tautransgenic mice. Science 2001; 293: 1491-1495.
17. Zampagni M, Wright D, Cascella R, D ' Adamio G, Casamenti F, Evangelisti E, et al. Novel S-Acyl glutathione derivatives prevent amyloid oxidative stress and cholinergic dysfunction in Alzheimer disease models. Free Radic Biol Med 2012; 52: 1362-1371.
18. Cascella R, Conti S, Tatini F, Evangelisti E, Scartabelli T, Casamenti F, et al. Extracellular 42-induced toxicity in rat brains. Biochim Biophys Acta chaperones prevent A 2013; 1832: 1217-1226.
19. Flood JF, Morley JE, Roberts E. Amnestic effects in mice of four synthetic peptides homologous to protein from patients with Alzheimer disease. Proc Natl Acad Sci USA amyloid 1991; 88: 3363-3366.
20. Pepeu G, Giovannelli L, Casamenti F, Scali C, Bartolini L. Amyloid beta-peptides injection into the cholinergic nuclei: Morphological, neurochemical and behavioral effects. Prog Brain Res 1996; 109: 273-282.
21. Kim MY, Zhang T, Kraus WL. Poly(ADP-ribosyl)ation by PARP-1: ' PAR-laying ' NAD - into a nuclear signal. Genes Dev 2005; 19: 1951-1967.
22. Nguewa PA, Fuertes MA, Valladares B, Alonso C, P e rez JM. Poly(ADP-ribose) polymerases: Homology, structural domains and functions, Novel therapeutical applications. Prog Biophys Mol Biol 2005; 88: 143-172.
23. Chiarugi A, Moskowitz MA. B-driven transcription Poly(ADP-ribose) polymerase-1 activity promotes NF- And microglial activation: Implication for neurodegenerative disorders. J Neurochem 2003; 85: 306-317.
24. Virag L, Szabo C. The therapeutic potential of poly(ADPribose) polymerase inhibitors. Pharmacol Rev 2002; 54: 375-429.
25. B u rkle A. Poly(ADP-ribose). The most elaborate metabolite of NAD -. FEBS J 2005; 272: 4576-4589.
26. David KK, Andrabi SA, Dawson TM, Dawson VL. Parthanatos, a messenger of death. Front Biosci 2009; 14: 1116-1128.
27. Chiarugi A. Intrinsic mechanisms of poly(ADP-ribose) neurotoxicity: Three hypotheses. Neurotoxicology 2005; 26: 847-855.
28. Ha HC, Snyder SH. Poly(ADP-ribose) polymerase-1 in the nervous system. Neurobiol Dis 2000; 7: 225-239.
29. Kirkland JB. Poly ADP-ribose polymerase-1 and health. Exp Biol Med 2010; 235: 561-568.
30. Shall S, de Murcia G. Poly(ADP-ribose) polymerase-1: What have we learned from the defi cient mouse model? Mutat Res 2000; 460: 1-15.
31. Mandir AS, Poitras MF, Berliner AR, Herring WJ, Guastella DB, Feldman A, et al. NMDA but not non-NMDA excitotoxicity is mediated by poly(ADPribose) polymerase. J Neurosci 2000; 20: 8005-8011.
32. Pieper AA, Verma A, Zhang J, Snyder SH. Poly(ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci 1999; 20: 171-181.
33. Zhang J, Lautar S, Huang S, Ramsey C, Cheung A, Li JH. GPI 6150 prevents H(2)O(2) cytotoxicity by inhibiting Poly (ADP-ribose)polymerase. Biochem Biophys Res Commun 2000; 278: 590-598.
34. Abeti R, Abramov AY, Duchen MR. Beta-Amyloid activates PARP causing astrocytic metabolic failure and neuronal death. Brain 2011; 134: 1658-1672.
35. Mandir AS, Przedborski S, Jackson-Lewis V, Wang ZQ, Simbulan-Rosenthal CM, Smulson ME, et al. Poly(ADPribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-Tetrahydropyridine (MPTP)-induced parkinsonism. Proc Natl Acad Sci USA 1999; 96: 5774-5779.
36. Kruman II, Culmsee C, Chan SL, Kruman Y, Guo Z, Penix L, Mattson MP. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000; 20: 6920-6926.
37. Li F, Chong ZZ, Maiese K. Navigating novel mechanisms of cellular plasticity with the NAD - precursor and nutrient nicotinamide. Front Biosci 2004; 9: 2500-2520.
38. Knip M, Douek IF, Moore WP, Gillmor HA, McLean AE, Bingley PJ, Gale EA. Safety of high-dose nicotinamide: A review. Diabetologia 2000; 43: 1337-1345.
39. Maiese K, Chong ZZ. Nicotinamide: Necessary nutrient emerges as a novel cytoprotectant for the brain. Trends Pharmacol Sci 2003; 24: 228-232.
40. Chong ZZ, Lin SH, Li F, Maiese K. The sirtuin inhibitor nicotinamide enhances neuronal cell survival during acute anoxic injury through Akt, Bad, PARP, and mitochondrial associated " anti-Apoptotic" pathways. Curr Neurovasc Res 2005; 2: 271e85.
41. Ungerstedt JS, Bl o mback M, S o derstr o m T. Nicotinamide is a potent inhibitor of proinfl ammatory cytokines. Clin Exp Immunol 2003; 131: 48-52.
42. Sakakibara Y, Mitha AP, Ogilvy CS, Maynard KI. Posttreatment with nicotinamide (vitamin b(3)) reduces the infarct volume following permanent focal cerebral ischemia in female Sprague-Dawley and Wistar rats. Neurosci Lett 2000; 281: 111-114.
43. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 4th ed. New York: Academic Press; 1998.
44. Uyanikgil Y, Turgut M, Ate ş U, Baka M, Yurtseven ME. Beneficial effects of melatonin on morphological changes in postnatal cerebellar tissue owing to epileptiform activity during pregnancy in rats: Light and immunohistochemical study. Brain Res Dev Brain Res 2005; 159: 79-86.
45. Baka M, Uyanikgil Y, Yurtseven M, Turgut M. Infl uence of penicillin-induced epileptic activity during pregnancy on postnatal hippocampal nestin expression in rats: Light and electron microscopic observations. Childs Nerv Syst 2004; 20: 726-733.
46. Latini A, Scussiato K, Borba Rosa R, Leipnitz G, Llesuy S, Bello-Klein A, et al. Induction of oxidative stress by L-2-hydroxyglutaric acid in rat brain. J Neurosci Res 2003; 74: 103-110.
47. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin-phenol reagent. J Biol Chem 1951; 193: 265-375.
48. Draper HH, Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol 1990; 186: 421-431.
49. Reznick AZ, Packer L. Oxidative damage to proteins: Spectrophotometric method for carbonyl assay. Methods Enzymol 1994; 233: 357-363.
50. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82: 70-77.
51. Goth L. A simple method for determination of serum catalase activity and revision of reference range. Clin Chim Acta 1991; 196: 143-152.
52. Delmas-Beauvieux MC, Peuchant E, Dumon MF, Receveur MC, Le Bras M, Clerc M. Relationship between red blood cell antioxidant enzymatic system status and lipoperoxidation during the acute phase of malaria. Clin Biochem 1995; 28: 163-169.
53. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967; 70: 158-169.
54. Bonnet JJ, Costentin J. Correlation between [3 H] dopamine specific uptake and [ 3 H] GBR 12783 specific binding during the maturation of rat striatum. Life Sci 1989; 44: 1759-1765.
55. Morel P, Fauconneau B, Page G, Mirbeau T, Huguet F. Inhibitory effects of ascorbic acid on dopamine uptake by rat striatal synaptosomes: Relationship to lipid peroxidation and oxidation of protein sulfhydryl groups. Neurosci Res 1998; 32: 171-179.
56. Wang H, Joseph JA. Quantifying cellular oxidative stress by dichlorofl uorescein assay using microplate reader. Free Radic Biol Med 1999; 27: 612-616.
57. Keller JN, Pang Z, Geddes JW, Begley JG, Germeyer A, Waeg G, Mattson MP. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: Role of the lipid peroxidation product 4-hydroxynonenal. J Neurochem 1997; 69: 273-284.
58. Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 1993; 15: 532-537.
59. Bustin SA. Absolute quantification of mRNA using real-Time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000; 25: 169-193.
60. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-Time quantitative PCR and the 2 (- Delta Delta C(T)) method. Methods 2001; 4: 402-408.
61. Li SX, Cui N, Zhang CL, Zhao XL, Yu SF, Xie KQ. Effect of subchronic exposure to acrylamide induced on the expression of bcl-2, bax and caspase-3 in the rat nervous system. Toxicology 2006; 217: 46-53.
62. Ferraris DV. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J Med Chem 2010; 53: 4561-4584.
63. Pandya KG, Patel MR, Lau-Cam CA. Comparative study of the binding characteristics to and inhibitory potencies towards PARP and in vivo antidiabetogenic potencies of taurine, 3-Aminobenzamide and nicotinamide. J Biomed Sci 2010; 17: S16.
64. Michikawa M. Neurodegenerative disorders and cholesterol. Curr Alzheimer Res 2004; 1: 271-275.
65. Green KN, Steffan JS, Martinez-Coria H, Sun X, Schreiber SS, Thompson LM, LaFerla FM. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci 2008; 28: 11500-11510.
66. Liu D, Pitta M, Jiang H, Lee JH, Zhang G, Chen X, et al. Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: Evidence for improved neuronal bioenergetics and autophagy procession. Neurobiol Aging 2013; 34: 1564-1580.
67. Sultana R, Butterfield DA. Role of oxidative stress in the progression of Alzheimer's disease. J Alzheimers Dis 2010; 19: 341-353.
68. Sultana R, Perluigi M, Butterfield DA. Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: Insights into mechanism of neurodegeneration from redox proteomics. Antioxid Redox Signal 2006; 8: 2021-2037.
69. Lovell MA, Xie C, Markesbery WR. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 2001; 22: 187-194.
70. Sowell RA, Owen JB, Butterfield DA. Proteomics in animal models of Alzheimer's and Parkinson's diseases. Ageing Res Rev 2009; 8: 1-17.
71. Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: Mechanisms, mutation, and disease. FASEB J 2003; 17: 1195-1214.
72. Lovell MA, Xie C, Markesbery WR. Decreased base excision repair and increased helicase activity in Alzheimer's disease brain. Brain Res 2000; 855: 116-123.
73. Yalcin A, Armagan G, Turunc E, Konyalioglu S, Kanit L. Potential neuroprotective effect of gamma-glutamylcysteine ethyl ester on rat brain against kainic acid-induced excitotoxicity. Free Radic Res 2010; 44: 513-521.
74. Turunc E, Kanit L, Yalcin A. Effect of gamma-glutamylcysteine ethylester on the levels of c-fos mRNA expression, glutathione and reactive oxygen species formation in kainic acid excitotoxicity. J Pharm Pharmacol 2010; 62: 1010-1017.
75. Pocernich CB, Butterfield DA. Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochim Biophys Acta 2012; 1822: 625-630.
76. Marcus DL, Thomas C, Rodriguez C, SimberkoffK, Tsai JS, Strafaci JA, Freedman ML. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp Neurol 1998; 150: 40-44.
77. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997; 23: 134-147.
78. Love S, Barber R, Wilcock GK. Increased poly(ADP-ribosyl) ation of nuclear proteins in Alzheimer's disease. Brain 1999; 122: 247-253.
79. Cecchi C, Fiorillo C, Sorbi S, Latorraca S, Nacmias B, Bagnoli S, et al. Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimer's patients. Free Radic Biol Med 2002; 33: 1372-1379.
80. Liu HP, Lin WY [80], Wu BT, Liu SH, Wang WF, Tsai CH, et al. Evaluation of the poly(ADP-ribose) polymerase-1 gene variants in Alzheimer's disease. J Clin Lab Anal 2010; 24: 182-186.
81. Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschmidt C. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci USA 1997; 94: 2642-2647.
82. Behl C, Sagara Y. Mechanism of amyloid beta protein induced neuronal cell death: Current concepts and future perspectives. J Neural Transm 1997; 49: 125-134.
83. Abeti R, Duchen MR. -Amyloid: Implications for Activation of PARP by oxidative stress induced by Alzheimer's disease. Neurochem Res 2012; 37: 2589-2596.
84. Cenini G, Sultana R, Memo M, Butterfield DA. Effects of oxidative and nitrosative stress in brain on p53 pro-Apoptotic protein in amnestic mild cognitive impairment and Alzheimer disease. Free Radic Biol Med 2008; 45: 81-85.
85. Paradis E, Douillard H, peptide of Alzheimer's Koutroumanis M, Goodyer C, LeBlanc A. Amyloid disease downregulates Bcl-2 and upregulates Bax expression in human neurons. J Neurosci 1996; 16: 533-539.
86. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-310.
87. Chang JR, Ghafouri M, Mukerjee R, Bagashev A, Chabrashvili T, Sawaya BE. Role of p53 in neurodegenerative diseases. Neurodegener Dis 2012; 9: 68-80.
88. de la Monte SM, Sohn YK, Wands Jr. Correlates of p53-And Fas (CD95)-mediated apoptosis in Alzheimer's disease. J Neurol Sci 1997; 52: 73-83.
89. MacGibbon GA, Lawlor PA, Sirimanne ES, Walton MR, Connor B, Young D, et al. Bax expression in mammalian neurons undergoing apoptosis, and in Alzheimer's disease hippocampus. Brain Res 1997; 750: 223-234.
90. Koriyama Y, Chiba K, Mohri T. Propentofylline protects beta-Amyloid protein-induced apoptosis in cultured rat hippocampal neurons. Eur J Pharmacol 2003; 458: 235-241.
91. Zhang Y, McLaughlin R, Goodyer C, LeBlanc A. Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons. J Cell Biol 2002; 156: 519-529.